TY - JOUR
T1 - Prevalence and risk factors of post-COVID-19 condition in adults and children at 6 and 12 months after hospital discharge
T2 - a prospective, cohort study in Moscow (StopCOVID)
AU - Sechenov StopCOVID Research Team
AU - Pazukhina, Ekaterina
AU - Andreeva, Margarita
AU - Spiridonova, Ekaterina
AU - Bobkova, Polina
AU - Shikhaleva, Anastasia
AU - El-Taravi, Yasmin
AU - Rumyantsev, Mikhail
AU - Gamirova, Aysylu
AU - Bairashevskaia, Anastasiia
AU - Petrova, Polina
AU - Baimukhambetova, Dina
AU - Pikuza, Maria
AU - Abdeeva, Elina
AU - Filippova, Yulia
AU - Deunezhewa, Salima
AU - Nekliudov, Nikita
AU - Bugaeva, Polina
AU - Bulanov, Nikolay
AU - Avdeev, Sergey
AU - Kapustina, Valentina
AU - Guekht, Alla
AU - DunnGalvin, Audrey
AU - Comberiati, Pasquale
AU - Peroni, Diego G.
AU - Apfelbacher, Christian
AU - Genuneit, Jon
AU - Reyes, Luis Felipe
AU - Brackel, Caroline L.H.
AU - Fomin, Victor
AU - Svistunov, Andrey A.
AU - Timashev, Peter
AU - Mazankova, Lyudmila
AU - Miroshina, Alexandra
AU - Samitova, Elmira
AU - Borzakova, Svetlana
AU - Bondarenko, Elena
AU - Korsunskiy, Anatoliy A.
AU - Carson, Gail
AU - Sigfrid, Louise
AU - Scott, Janet T.
AU - Greenhawt, Matthew
AU - Buonsenso, Danilo
AU - Semple, Malcolm G.
AU - Warner, John O.
AU - Olliaro, Piero
AU - Needham, Dale M.
AU - Glybochko, Petr
AU - Butnaru, Denis
AU - Osmanov, Ismail M.
AU - Munblit, Daniel
N1 - Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Background: Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors. Methods: Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge. Results: One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47–53) in adults and 20% (95% CI 16–24) in children at 6 months, with decline to 34% (95% CI 31–37) and 11% (95% CI 8–14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47). Conclusions: Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.
AB - Background: Previous studies assessing the prevalence of COVID-19 sequelae in adults and children were performed in the absence of an agreed definition. We investigated prevalence of post-COVID-19 condition (PCC) (WHO definition), at 6- and 12-months follow-up, amongst previously hospitalised adults and children and assessed risk factors. Methods: Prospective cohort study of children and adults with confirmed COVID-19 in Moscow, hospitalised between April and August, 2020. Two follow-up telephone interviews, using the International Severe Acute Respiratory and Emerging Infection Consortium survey, were performed at 6 and 12 months after discharge. Results: One thousand thirteen of 2509 (40%) of adults and 360 of 849 (42%) of children discharged participated in both the 6- and 12-month follow-ups. PCC prevalence was 50% (95% CI 47–53) in adults and 20% (95% CI 16–24) in children at 6 months, with decline to 34% (95% CI 31–37) and 11% (95% CI 8–14), respectively, at 12 months. In adults, female sex was associated with PCC at 6- and 12-month follow-up (OR 2.04, 95% CI 1.57 to 2.65) and (OR 2.04, 1.54 to 2.69), respectively. Pre-existing hypertension (OR 1.42, 1.04 to 1.94) was associated with post-COVID-19 condition at 12 months. In children, neurological comorbidities were associated with PCC both at 6 months (OR 4.38, 1.36 to 15.67) and 12 months (OR 8.96, 2.55 to 34.82) while allergic respiratory diseases were associated at 12 months (OR 2.66, 1.04 to 6.47). Conclusions: Although prevalence of PCC declined one year after discharge, one in three adults and one in ten children experienced ongoing sequelae. In adults, females and persons with pre-existing hypertension, and in children, persons with neurological comorbidities or allergic respiratory diseases are at higher risk of PCC.
KW - Adults
KW - Children
KW - COVID-19
KW - COVID-19 sequelae
KW - Long COVID
KW - PASC
KW - Post-acute sequelae of SARS-CoV-2 infection
KW - Post-COVID-19 condition
KW - Prevalence
KW - Risk factor
UR - https://www.scopus.com/pages/publications/85133568517
U2 - 10.1186/s12916-022-02448-4
DO - 10.1186/s12916-022-02448-4
M3 - Article
C2 - 35794549
AN - SCOPUS:85133568517
SN - 1741-7015
VL - 20
JO - BMC Medicine
JF - BMC Medicine
IS - 1
M1 - 244
ER -
SDG 3 Good Health and Well-being